These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28715695)

  • 41. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways.
    Shahbazian D; Parsyan A; Petroulakis E; Hershey J; Sonenberg N
    Cell Cycle; 2010 Oct; 9(20):4106-9. PubMed ID: 20948310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
    Hua H; Zhu Y; Song YH
    Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway.
    Liu L; Dong Z; Liang J; Cao C; Sun J; Ding Y; Wu D
    Oncogene; 2014 Feb; 33(7):909-20. PubMed ID: 23812429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection.
    Aljumah AA; Kuriry H; Faisal N; Alghamdi H
    Ann Saudi Med; 2018; 38(5):358-365. PubMed ID: 30284991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway.
    Man J; Zhou W; Zuo S; Zhao X; Wang Q; Ma H; Li HY
    Biochem Pharmacol; 2023 Jul; 213():115615. PubMed ID: 37211171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C.
    Saito T; Sugimoto M; Okumoto K; Haga H; Katsumi T; Mizuno K; Nishina T; Sato S; Igarashi K; Maki H; Tomita M; Ueno Y; Soga T
    World J Gastroenterol; 2016 Jul; 22(27):6224-34. PubMed ID: 27468212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy.
    Fu N; Du H; Li D; Lu Y; Li W; Wang Y; Kong L; Du J; Zhao S; Ren W; Han F; Wang R; Zhang Y; Nan Y
    Life Sci; 2020 Sep; 256():117911. PubMed ID: 32504756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues.
    Bortolami M; Comparato A; Benna C; Errico A; Maretto I; Pucciarelli S; Cillo U; Farinati F
    PLoS One; 2020; 15(12):e0244356. PubMed ID: 33362215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma.
    Mei L; Sun H; Yan Y; Ji H; Su Q; Chang L; Wang L
    Int J Biol Sci; 2024; 20(11):4178-4189. PubMed ID: 39247820
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
    Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
    PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma.
    Lee WP; Lan KH; Li CP; Chao Y; Lin HC; Lee SD
    Biochim Biophys Acta; 2016 Apr; 1862(4):837-849. PubMed ID: 26791804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 55. eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.
    Sun L; Liu S; Wang X; Zheng X; Chen Y; Shen H
    J Transl Med; 2021 May; 19(1):216. PubMed ID: 34016142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma.
    Tai DI; Tsai SL; Chang YH; Huang SN; Chen TC; Chang KS; Liaw YF
    Cancer; 2000 Dec; 89(11):2274-81. PubMed ID: 11147598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
    Del Campo JA; García-Valdecasas M; Gil-Gómez A; Rojas Á; Gallego P; Ampuero J; Gallego-Durán R; Pastor H; Grande L; Padillo FJ; Muntané J; Romero-Gómez M
    PLoS One; 2018; 13(1):e0191805. PubMed ID: 29385181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduction of double-stranded RNA-activated protein kinase in hepatocellular carcinoma associated with hepatitis B virus.
    Chen GG; Lai PB; Ho RL; Chan PK; Xu H; Wong J; Lau WY
    J Med Virol; 2004 Jun; 73(2):187-94. PubMed ID: 15122791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
    Tapia O; Riquelme I; Leal P; Sandoval A; Aedo S; Weber H; Letelier P; Bellolio E; Villaseca M; Garcia P; Roa JC
    Virchows Arch; 2014 Jul; 465(1):25-33. PubMed ID: 24844205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.